Treatment of varicella-zoster virus infections with adenine arabinoside
- PMID: 165242
- DOI: 10.1093/infdis/131.3.225
Treatment of varicella-zoster virus infections with adenine arabinoside
Abstract
Twenty-three patients with complicated varicella-zoster virus infections were treated with adenine arabinoside. Of 14 patients with herpes zoster, 13 had malignancy treated with irradiation and cytotoxic agents or steroids. Although the duration of active vesicle formation in these patients ranged from two to 14 days before therapy, no new lesions appeared after the fourth day of treatment with adenine arabinoside. Zoster encephalitis developed in one patient on the third day of treatment, and severe postherpetic neuralgia was seen in three patients. Of nine treated patients with primary varicella, six improved, including five with evidence of varicella pneumonia. Two of the three patients with varicella who died were immunosuppressed and had progressive viral pneumonia with persistently high titers of virus in vesicular fluid; the third pateint was a child with Reye's syndrome. Double-blind controlled studies will be necessary to demonstrate the efficacy of adenine arabinoside in the treatment of infections with varicella-zoster virus.
Similar articles
-
[Adenine arabinoside treatment of varicella and generalized herpes zoster in 43 immunosuppressed patients].Nouv Presse Med. 1982 Nov 27;11(48):3547-50. Nouv Presse Med. 1982. PMID: 7155866 French.
-
Varicella-zoster virus infections: chronic disease in the immunocompromised host: evidence for persistent excretion of virus.Pediatr Infect Dis J. 1989 Sep;8(9):584-5. Pediatr Infect Dis J. 1989. PMID: 2552389 Review. No abstract available.
-
Comparative use of adenine arabinoside and adenine arabinoside monophosphate in varicella and disseminated zoster in immunosuppressed patients.J Med Virol. 1983;12(2):149-53. doi: 10.1002/jmv.1890120209. J Med Virol. 1983. PMID: 6194253
-
[Preliminary clinical experiences with adenine arabinoside monophosphate (ARA-AMP) in encephalitis due to viruses of the herpes group and varicella/zoster infections (author's transl)].Klin Padiatr. 1979 Nov;191(6):566-71. Klin Padiatr. 1979. PMID: 92592 German.
-
Varicella-zoster virus: atypical presentations and unusual complications.J Infect Dis. 2002 Oct 15;186 Suppl 1:S91-8. doi: 10.1086/342963. J Infect Dis. 2002. PMID: 12353193 Review.
Cited by
-
A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1.Vet Ophthalmol. 2016 Jul;19 Suppl 1(Suppl 1):119-30. doi: 10.1111/vop.12375. Epub 2016 Apr 19. Vet Ophthalmol. 2016. PMID: 27091747 Free PMC article. Review.
-
Vidarabine: a preliminary review of its pharmacological properties and therapeutic use.Drugs. 1980 Oct;20(4):267-82. doi: 10.2165/00003495-198020040-00002. Drugs. 1980. PMID: 6998693 Review.
-
Prospective double-blind evaluation of topical adenine arabinoside in male herpes progenitalis.Antimicrob Agents Chemother. 1975 Dec;8(6):693-7. doi: 10.1128/AAC.8.6.693. Antimicrob Agents Chemother. 1975. PMID: 174489 Free PMC article. Clinical Trial.
-
Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.Drugs. 1999 Feb;57(2):187-206. doi: 10.2165/00003495-199957020-00005. Drugs. 1999. PMID: 10188760 Review.
-
In vitro susceptibility of varicella-zoster virus to acyclovir.Antimicrob Agents Chemother. 1980 Sep;18(3):443-7. doi: 10.1128/AAC.18.3.443. Antimicrob Agents Chemother. 1980. PMID: 6252836 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources